These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1299 related items for PubMed ID: 14499784

  • 1. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.
    Summers RW, Elliott DE, Qadir K, Urban JF, Thompson R, Weinstock JV.
    Am J Gastroenterol; 2003 Sep; 98(9):2034-41. PubMed ID: 14499784
    [Abstract] [Full Text] [Related]

  • 2. Helminth therapy (worms) for induction of remission in inflammatory bowel disease.
    Garg SK, Croft AM, Bager P.
    Cochrane Database Syst Rev; 2014 Jan 20; 2014(1):CD009400. PubMed ID: 24442917
    [Abstract] [Full Text] [Related]

  • 3. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis.
    Levine DS, Fischer SH, Christie DL, Haggitt RC, Ochs HD.
    Am J Gastroenterol; 1992 Jan 20; 87(1):91-100. PubMed ID: 1728132
    [Abstract] [Full Text] [Related]

  • 4. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity.
    Clara I, Lix LM, Walker JR, Graff LA, Miller N, Rogala L, Rawsthorne P, Bernstein CN.
    Am J Gastroenterol; 2009 Jul 20; 104(7):1754-63. PubMed ID: 19455122
    [Abstract] [Full Text] [Related]

  • 5. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A.
    Am J Gastroenterol; 2009 Feb 20; 104(2):437-43. PubMed ID: 19174792
    [Abstract] [Full Text] [Related]

  • 6. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission.
    Herrlinger KR, Noftz MK, Dalhoff K, Ludwig D, Stange EF, Fellermann K.
    Am J Gastroenterol; 2002 Feb 20; 97(2):377-81. PubMed ID: 11866276
    [Abstract] [Full Text] [Related]

  • 7. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors.
    Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES.
    Am J Gastroenterol; 2002 Feb 20; 97(2):389-96. PubMed ID: 11866278
    [Abstract] [Full Text] [Related]

  • 8. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire.
    Casellas F, Alcalá MJ, Prieto L, Miró JR, Malagelada JR.
    Am J Gastroenterol; 2004 Mar 20; 99(3):457-61. PubMed ID: 15056085
    [Abstract] [Full Text] [Related]

  • 9. Inflammatory bowel diseases: controversies in the use of diagnostic procedures.
    Vucelic B.
    Dig Dis; 2009 Mar 20; 27(3):269-77. PubMed ID: 19786751
    [Abstract] [Full Text] [Related]

  • 10. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005.
    Herrinton LJ, Liu L, Fireman B, Lewis JD, Allison JE, Flowers N, Hutfless S, Velayos FS, Abramson O, Altschuler A, Perry GS.
    Gastroenterology; 2009 Aug 20; 137(2):502-11. PubMed ID: 19445944
    [Abstract] [Full Text] [Related]

  • 11. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.
    Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, Triadaphyllou G.
    Am J Gastroenterol; 2004 Jun 20; 99(6):1122-8. PubMed ID: 15180735
    [Abstract] [Full Text] [Related]

  • 12. The state of the art in the management of inflammatory bowel disease.
    Hanauer SB, Present DH.
    Rev Gastroenterol Disord; 2003 Jun 20; 3(2):81-92. PubMed ID: 12776005
    [Abstract] [Full Text] [Related]

  • 13. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
    Pearce CB, Lawrance IC.
    J Gastroenterol Hepatol; 2007 Oct 20; 22(10):1671-7. PubMed ID: 17845695
    [Abstract] [Full Text] [Related]

  • 14. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S, Florin TH, Khalil D, Zhang MF, Patel K, Hamilton I, Hart DN.
    Am J Gastroenterol; 2001 Oct 20; 96(10):2946-56. PubMed ID: 11693331
    [Abstract] [Full Text] [Related]

  • 15. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study).
    Henriksen M, Jahnsen J, Lygren I, Sauar J, Schulz T, Stray N, Vatn MH, Moum B, Ibsen Study Group.
    Scand J Gastroenterol; 2006 Sep 20; 41(9):1037-43. PubMed ID: 16938716
    [Abstract] [Full Text] [Related]

  • 16. Low-dose naltrexone therapy improves active Crohn's disease.
    Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS.
    Am J Gastroenterol; 2007 Apr 20; 102(4):820-8. PubMed ID: 17222320
    [Abstract] [Full Text] [Related]

  • 17. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ.
    Am J Gastroenterol; 2008 Jan 20; 103(1):162-9. PubMed ID: 17916108
    [Abstract] [Full Text] [Related]

  • 18. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study.
    Hafer A, Krämer S, Duncker S, Krüger M, Manns MP, Bischoff SC.
    BMC Gastroenterol; 2007 Sep 04; 7():36. PubMed ID: 17784949
    [Abstract] [Full Text] [Related]

  • 19. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.
    Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA, Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU).
    Aliment Pharmacol Ther; 2004 Dec 04; 20(11-12):1347-52. PubMed ID: 15606397
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study.
    Martín de Carpi J, Vilar P, Prieto G, García Novo MD, Ribes C, Varea V.
    J Pediatr Gastroenterol Nutr; 2008 Apr 04; 46(4):386-91. PubMed ID: 18367949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.